APUS · Apimeds Pharmaceuticals US, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $1.63M | — | $98.54K | |
| $24.51M | $10.28M | $1.28M | $648.89K | |
| $27.35M | $11.91M | $1.28M | — | |
| -$27.35M | -$11.91M | -$1.28M | -$747.44K | |
| $4.31M | $283.01K | $117.72K | $38.07K | |
| $114.12K | $107.6K | $2824 | $7811 | |
| -$30.82M | $5.91M | -$114.9K | -$30.26K | |
| -$58.17M | -$6M | -$1.39M | -$777.69K | |
| USD/shares | -$36.80 | -$5.50 | -$1.80 | -$1.70 |
| USD/shares | -$36.80 | -$5.50 | -$1.80 | -$1.70 |
| shares | — | 1.09M | 790.39K | 459.83K |
| shares | — | 1.09M | 790.39K | — |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 20 similar-size Drug Manufacturers - Specialty & Generic companies (of 99 listed).